Stephen Gruber, M.D., Ph.D., M.P.H.

sgruber@coh.org
800-826-4673
Stephen Gruber
Vice President, City of Hope National Medical Center; Director, Center for Precision Medicine; Medical Oncologist
Clinical Expertise
Medical Oncology
Epidemiology
Research Area
Precision Medicine
Genomics of Cancer
Appointments
Professor, Division of Molecular Pharmacology, Department of Medical Oncology & Therapeutics Research
Clinical Teams
Genetic Cancer Risk Assessment
Medical Oncology & Therapeutics Research
An internationally recognized cancer geneticist and oncologist, Stephen Gruber, M.D., Ph.D., M.P.H., is a physician-scientist who focuses his clinical practice and research program on precision medicine and the genomics of cancer in order to improve treatment and care for cancer patients and their families. Dr. Gruber is an expert in Lynch syndrome and hereditary susceptibility to colorectal cancer, and he has broad experience in the care of patients and families with inherited susceptibility to cancer.
 
Dr. Gruber leads the Center for Precision Medicine at City of Hope. Precision medicine uses genomic-driven insights, clinical expertise, and advanced analytics to pioneer personalized prevention and treatment plans to transform the outcomes and quality of life for patients, their families and the community. His research program focuses on the genetic epidemiology of cancer, with an emphasis on colorectal cancer, melanoma and other solid tumors, bringing clinical cancer genetics and translational research to cancer prevention.
 
Dr. Gruber earned his Master of Public Health and Ph.D. in epidemiology from Yale University. He earned his medical degree and completed his residency in internal medicine at the University of Pennsylvania and completed fellowships in medical oncology at Johns Hopkins and in clinical medical genetics at University of Michigan. Dr. Gruber has been continuously funded by the National Institutes of Health since 1998 and is an elected member of the American Society of Clinical Investigation.
Location
Education & Experience
Board Certifications

  • 2008-2018, Diplomate, Recertified in Medical Oncology

  • 2004-2005, Visiting Scientist, Sabbatical, Institut Catala d’Oncologia, Barcelona, Spain

  • 1998-2008, Diplomate in Medical Oncology

  • 1995-2005, Diplomate in Internal Medicine

  • 1993, Diplomate of the National Board of Medical Examiners

Degrees

  • 1992, M.D., University of Pennsylvania, Philadelphia, PA

  • 1988, Ph.D., Epidemiology, Yale University, New Haven, CT

  • 1986, M.P.H., Graduate School, Yale University, New Haven, CT (Distinction)

  • 1984, B.A., English/Biology, University of Pennsylvania, Philadelphia, PA

Fellowship

  • 1994-1997, M.D., Medical Oncology, Johns Hopkins Hospital, Baltimore

Residency

  • 1997-1999, Clinical Medical Genetics, University of Michigan, Ann Arbor, MI

  • 1993-1994, Internal Medicine, University of Pennsylvania, Philadelphia, PA

Internship

  • 1992-1993, Internal Medicine, University of Pennsylvania, Philadelphia, PA

Professional Experience

  • 2019-present, Director, Center of Precision Medicine, and Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California

  • 2011-2019, Professor, Preventive Medicine, University of Southern California, Los Angeles, CA

  • 2011-2019, Professor, Medicine, University of Southern California, Los Angeles, CA

  • 2011-2017, Director, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA

  • 2011-2012, Adjunct Professor, Internal Medicine, University of Michigan, Ann Arbor, MI

  • 2008-2011, Professor, Internal Medicine, Epidemiology, and Human Genetics, University of Michigan, Ann Arbor, MI

  • 2004-2008, Associate Professor, Internal Medicine, Epidemiology and Human Genetics (tenure), University of Michigan, Ann Arbor, MI

  • 2002-2004, Assistant Professor, Human Genetics, University of Michigan, Ann Arbor, MI

  • 1997-2004, Assistant Professor, Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, MI

Awards & Memberships
Awards

  • 2017, Jane & Kris Popovich Endowed Chair in Cancer Research, University of Southern California

  • 2016, The Niehaus Southworth Weissenbach Award and Visiting Professor in Clinical Cancer Genetics, Memorial Sloan Kettering

  • 2013, Lifetime Achievement Award, Collaborative Group of the Americas on Inherited Colorectal Cancer

  • 2012, H. Leslie and Elaine S. Hoffman Cancer Research Chair, University of Southern California

  • 2011, University of Michigan League of Research Excellence

  • 2006, H. Marvin Pollard Professor of Internal Medicine, University of Michigan

  • 2003, Elected to American Society of Clinical Investigation

  • 2000, Jerome Conn Award for Excellence in Research

  • 1994, Humaneness in Medicine, Philadelphia County Medical Society

  • 1994, Penn Pearls Teaching Award

  • 1992, Alfred Stengel Memorial Prize

  • 1989-1992, Penn Medical Scholar

  • 1986-1988, NIH Cancer Training Grant

  • 1986, Distinction, Yale University

Memberships

  • 1996-present, American Society of Clinical Oncology

  • 1997-present, American Association for the Advancement of Science

  • 2003, elected, American Society of Clinical Investigation

  • 1999, American Association of Cancer Research

  • 1998, American Society of Human Genetics

Publications
  • Schmit SL, Edlund CK, Schumacher FR, Gong J, Harrison TA, Huyghe JR,…[175 other authors], Conti DV, Gruber SB. Novel Common Susceptibility Loci for Colorectal Cancer. J Natl Cancer Inst. 2018 Feb 1;111(2):146-157, 2019.
  • McDonnell KJ, Chemler JA, Bartels PL, O’Brien E, Marvin ML, Ortega J, Stern RH, Raskin L, Li G-M, Sherman DH, Barton JK, Gruber SB. A human MUTYH variant linking colonic polyposis to redox degradation of the [4Fe4S]2+ cluster. Nature Chemistry 2018, 10(8):873-880.
  • Maoz A, Rennert G, Gruber SB. T-Cell Transfer Therapy Targeting Mutant KRAS. N Engl J Med 2017 Feb 16;376(7):e11, 2017.
  • Rozek LS, Schmit SL, Greenson JK, Tomsho LP, Rennert HS, Rennert G, Gruber SB. Tumor- Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and survival from colorectal cancer. J Natl Cancer Inst. 2016 Aug;108(8), 2016.
  • Mukherjee B, Delancey JO, Raskin L, Everett J, Jeter J, Begg CB, Orlow I, Berwick M, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Culver HA, Rosso S, Zanetti R, Kanetsky PA, From L, Gruber SB, Gem Study Investigators. Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. J Natl Cancer Inst 104:953-956, 2012.
  • Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, Redman B, Thomas NE, Gruber SB. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16:267-273, 2006.
  • Douglas JA, Gruber SB, Meister KA, Bonner J, Watson P, Krush AJ, Lynch HT. History and molecular genetics of Lynch syndrome in Family G: a century later. JAMA 294:2195-2202, 2005.
  • Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G. Statins and the risk of colorectal cancer. N Engl J Med 352:2184-2192, 2005.
  • Greenson JK, Bonner JD, Ben-Yzhak O, Cohen HI, Miselevich I, Resnick MB, Trougouboff P, Tomsho LD, Kim E, Low M, Almog R, Rennert G, Gruber SB. Phenotype of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol 27:563-570, 2003.
  • Gruber SB, Ellis NA, Scott KK, Almog R, Kolachana P, Bonner JD, Kirchhoff T, Tomsho LP, Nafa K, Pierce H, Low M, Satagopan J, Rennert H, Huang H, Greenson JK, Groden J, Rapaport B, Shia J, Johnson S, Gregersen PK, Harris CC, Boyd J, Rennert G, Offit K. BLM heterozygosity and the risk of colorectal cancer. Science 297:2013, 2002.
  • Gruber SB, Entius MM, Petersen GM, Laken SJ, Longo PA, Boyer R, Levin AM, Mujumdar UJ, Trent JM, Kinzler KW, Vogelstein B, Hamilton SR, Polymeropoulos MH, Offerhaus GJ, Giardiello FM. Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Res 58:5267-5270, 1998.
  • Laken SJ, Petersen GM, Gruber SB, Oddoux C, Ostrer H, Giardiello FM, Hamilton SR, Hampel H, Markowitz A, Klimstra D, Jhanwar S, Winawer S, Offit K, Luce MC, Kinzler KW, Vogelstein B. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 17:79-83, 1997.